365 related articles for article (PubMed ID: 36238195)
1. Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis.
Carnero Contentti E; Correale J
Drug Des Devel Ther; 2022; 16():3473-3490. PubMed ID: 36238195
[TBL] [Abstract][Full Text] [Related]
2. Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis.
Steinmaurer A; Wimmer I; Berger T; Rommer PS; Sellner J
Curr Pharm Des; 2022; 28(6):437-444. PubMed ID: 34218776
[TBL] [Abstract][Full Text] [Related]
3. Bruton's tyrosine kinase as a promising therapeutic target for multiple sclerosis.
Saberi D; Geladaris A; Dybowski S; Weber MS
Expert Opin Ther Targets; 2023; 27(4-5):347-359. PubMed ID: 37272515
[TBL] [Abstract][Full Text] [Related]
4. A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis.
Airas L; Bermel RA; Chitnis T; Hartung HP; Nakahara J; Stuve O; Williams MJ; Kieseier BC; Wiendl H
Ther Adv Neurol Disord; 2024; 17():17562864241233041. PubMed ID: 38638671
[TBL] [Abstract][Full Text] [Related]
5. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease.
Torke S; Pretzsch R; Häusler D; Haselmayer P; Grenningloh R; Boschert U; Brück W; Weber MS
Acta Neuropathol; 2020 Oct; 140(4):535-548. PubMed ID: 32761407
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases.
De Bondt M; Renders J; Struyf S; Hellings N
Autoimmun Rev; 2024 May; 23(5):103532. PubMed ID: 38521213
[TBL] [Abstract][Full Text] [Related]
8. Bruton's Tyrosine Kinase Inhibition in Multiple Sclerosis.
Schneider R; Oh J
Curr Neurol Neurosci Rep; 2022 Nov; 22(11):721-734. PubMed ID: 36301434
[TBL] [Abstract][Full Text] [Related]
9. Bruton's tyrosine kinase inhibition reduces disease severity in a model of secondary progressive autoimmune demyelination.
Evonuk KS; Wang S; Mattie J; Cracchiolo CJ; Mager R; Ferenčić Ž; Sprague E; Carrier B; Schofield K; Martinez E; Stewart Z; Petrosino T; Johnson GA; Yusuf I; Plaisted W; Naiman Z; Delp T; Carter L; Marušić S
Acta Neuropathol Commun; 2023 Jul; 11(1):115. PubMed ID: 37438842
[TBL] [Abstract][Full Text] [Related]
10. Bruton's Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy.
García-Merino A
Cells; 2021 Sep; 10(10):. PubMed ID: 34685540
[TBL] [Abstract][Full Text] [Related]
11. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
Ringheim GE; Wampole M; Oberoi K
Front Immunol; 2021; 12():662223. PubMed ID: 34803999
[TBL] [Abstract][Full Text] [Related]
12. Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment.
Good L; Benner B; Carson WE
Cancer Immunol Immunother; 2021 Sep; 70(9):2439-2451. PubMed ID: 33818636
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Bruton´s tyrosine kinase as a novel therapeutic approach in multiple sclerosis.
Torke S; Weber MS
Expert Opin Investig Drugs; 2020 Oct; 29(10):1143-1150. PubMed ID: 32772592
[TBL] [Abstract][Full Text] [Related]
14. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.
Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D
Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645
[TBL] [Abstract][Full Text] [Related]
15. The role of Bruton's tyrosine kinase in the immune system and disease.
McDonald C; Xanthopoulos C; Kostareli E
Immunology; 2021 Dec; 164(4):722-736. PubMed ID: 34534359
[TBL] [Abstract][Full Text] [Related]
16. Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis.
Himmelbauer MK; Bajrami B; Basile R; Capacci A; Chen T; Choi CK; Gilfillan R; Gonzalez-Lopez de Turiso F; Gu C; Hoemberger M; Johnson DS; Jones JH; Kadakia E; Kirkland M; Lin EY; Liu Y; Ma B; Magee T; Mantena S; Marx IE; Metrick CM; Mingueneau M; Murugan P; Muste CA; Nadella P; Nevalainen M; Parker Harp CR; Pattaropong V; Pietrasiewicz A; Prince RJ; Purgett TJ; Santoro JC; Schulz J; Sciabola S; Tang H; Vandeveer HG; Wang T; Yousaf Z; Helal CJ; Hopkins BT
J Med Chem; 2024 May; 67(10):8122-8140. PubMed ID: 38712838
[TBL] [Abstract][Full Text] [Related]
17. Bruton's Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease.
Neys SFH; Rip J; Hendriks RW; Corneth OBJ
Drugs; 2021 Sep; 81(14):1605-1626. PubMed ID: 34609725
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Novel Bruton's Tyrosine Kinase PROTACs with Enhanced Selectivity and Cellular Efficacy.
Li YQ; Lannigan WG; Davoodi S; Daryaee F; Corrionero A; Alfonso P; Rodriguez-Santamaria JA; Wang N; Haley JD; Tonge PJ
J Med Chem; 2023 Jun; 66(11):7454-7474. PubMed ID: 37195170
[TBL] [Abstract][Full Text] [Related]
19. Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors: A Review.
Dybowski S; Torke S; Weber MS
JAMA Neurol; 2023 Apr; 80(4):404-414. PubMed ID: 36780171
[TBL] [Abstract][Full Text] [Related]
20. Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations.
Krämer J; Wiendl H
Curr Opin Neurol; 2024 Jun; 37(3):237-244. PubMed ID: 38533819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
